Levosimendan does not improve survival time in a rat model of verapamil toxicity

Journal of Medical Toxicology

Volumn 5, Issue 1, 2009, Pages 3-7

  Abraham, Michael K ^a   Scott, Sara B ^a   Meltzer, Andrew ^b   Barrueto Jr , Fermin ^a,b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Levosimendan; Toxicity; Verapamil

Indexed keywords

CALCIUM ION; LEVOSIMENDAN; PHOSPHODIESTERASE; PLACEBO; SODIUM CHLORIDE; TROPONIN C; VERAPAMIL; ANTIDOTE; CALCIUM CHANNEL BLOCKING AGENT; HYDRAZONE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PYRIDAZINE DERIVATIVE; SIMENDAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASYSTOLE; BRADYCARDIA; CONTROLLED STUDY; CORE TEMPERATURE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG INTOXICATION; DRUG MECHANISM; DRUG OVERDOSE; DRUG SENSITIZATION; ELECTROCARDIOGRAPHY; ENZYME INHIBITION; FEMORAL VEIN; HUMAN; HYPOTENSION; MALE; NONHUMAN; PROTEIN BINDING; RAT; RISK BENEFIT ANALYSIS; SURVIVAL TIME; VEIN CATHETERIZATION; ANIMAL; BODY TEMPERATURE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG INTERACTION; HEART ARREST; HEART RATE; PATHOPHYSIOLOGY; TIME; WISTAR RAT;

ANIMALS; ANTIDOTES; BODY TEMPERATURE; BRADYCARDIA; CALCIUM CHANNEL BLOCKERS; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; HEART ARREST; HEART RATE; HYDRAZONES; HYPOTENSION; MALE; MODELS, ANIMAL; PHOSPHODIESTERASE INHIBITORS; PYRIDAZINES; RATS; RATS, WISTAR; TIME FACTORS; VERAPAMIL;

EID: 65249144439     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/BF03160973     Document Type: Article

References (12)

1. Veltri JC, Litovitz TL. 1983 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1984;2(5):420-443.
2. Lai MW, Klein-Schwartz W, Rodgers GC, et al. 2005 Annual Report of the American Association of Poison Control Centers' national poisoning and exposure database. Clin Toxicol (Phila) 2006;44(6-7):803-932.
3. De Luca L, Colucci WS, Nieminen MS, et al. Evidence-based use of levosimendan in different clinical settings. Eur Heart J 2006;27(16):1908-1920.
4. Pollesello P, Ovaska M, Kaivola J, et al. Binding of a new Ca2 sensitizer, levosimendan, to recombinant human cardiac troponin C: a molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. J Biol Chem 1994;269(46):28584-28590.
5. Tebbutt S, Harvey M, Nicholson T, et al. Intralipid pro-longs survival in a rat model of verapamil toxicity. Acad Emerg Med 2006;13(2):134-139.
6. Kivikko M, Lehtonen L, Colucci WS. Sustained hemody-namic effects of intravenous levosimendan. Circulation 2003; 107(1):81-86.
7. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297(17): 1883-1891.
8. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemo-dynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000;102(18):2222-2227.
9. Ajiro Y, Hagiwara N, Katsube Y, et al. Levosimendan increases L-type Ca(2) current via phosphodiesterase-3 inhibition in human cardiac myocytes. Eur J Pharmacol 2002;435(1):27-33.
10. Erdei N, Papp Z, Pollesello P, et al. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. Br J Pharmacol 2006;148(5):696-702.
11. Dworschak M, Breukelmann D, Hannon JD. The im-pact of isoflurane during simulated ischemia/reoxygenation on intracellular calcium, contractile function, and arrhyth-mia in ventricular myocytes. Anesth Analg 2004;99(5): 1302-1307.
12. Hanouz JL, Vivien B, Gueugniaud PY, et al. Comparison of the effects of sevoflurane, isoflurane and halothane on rat myocardium. Br J Anaesth. 1998;80(5):621-627.